Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First head-to-head pivotal trial of ELVN-001

Next Previous
Trial Profile

First head-to-head pivotal trial of ELVN-001

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELVN-001 (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ENABLE-2
  • Sponsors Enliven Therapeutics

Most Recent Events

  • 11 Jun 2026 According to an Enliven Therapeutics media release, Additional details of the Phase 3 trial design are expected to be finalized following further discussions with the FDA, including at a planned End-of-Phase 2 meeting anticipated in the third quarter of 2026.
  • 08 Jan 2026 According to an Enliven Therapeutics media release, the company is preparing for upcoming regulatory interactions with the FDA to align on dose selection and support initiation of this Phase 3 trial in 2H 2026. Initiation of ENABLE-2, this Phase 3 clinical trial of ELVN-001 is also expected in 2H 2026
  • 07 Jan 2026 According to an Enliven Therapeutics media release, the company advance ELVN-001 into a pivotal Phase 3 trial in patients with chronic myeloid leukemia later this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top